regadenoson: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
regadenoson: clinical details
Prescribing considerations
- Diagnostic use in adults only; administer in a medical facility with continuous ECG capability, frequent vital-sign assessment and resuscitation resources.
- Review recent myocardial infarction or active ischaemic symptoms, blood-pressure control, volume status, atrial fibrillation or flutter, long-QT syndrome and seizure risk.
- Use caution in asthma, COPD or suspected bronchoconstrictive disease; bronchodilator therapy and resuscitative measures should be available.
- Review methylxanthines, dipyridamole and medicines that lower seizure threshold before the procedure.
- Aminophylline can attenuate severe or persistent reactions but should not be used solely to terminate a regadenoson-induced seizure.
Contraindications and cautions
- Hypersensitivity to regadenoson or an excipient
- Second- or third-degree AV block or sinus-node dysfunction without a functioning pacemaker
- Unstabilised unstable angina
- Severe hypotension
- Decompensated heart failure
Monitoring
- Monitor ECG, heart rate and blood pressure until they return to the patient's pre-administration state.
- Observe for myocardial ischaemia, conduction disturbance, clinically significant blood-pressure change, bronchoconstriction, hypersensitivity, neurological events and seizures.
- Keep the patient sitting or lying during early monitoring and ensure trained staff and resuscitation equipment are immediately available.
Clinical pharmacology
Regadenoson is a relatively selective, low-affinity A2A adenosine-receptor agonist that produces rapid, short-lived coronary hyperaemia. Its concentration-time profile is multiphasic; elimination is substantially renal, with much excreted unchanged.
Formulation and product differences
- The selected UK product is a clear, colourless solution for intravenous injection in a single-use glass vial.
- Excipients include phosphate salts, propylene glycol, disodium edetate and water for injections.
- Do not mix with other medicines where compatibility has not been established; inspect for particles or discolouration before use.
regadenoson preparations and strengths
Injection
Route: Parenteral
Strengths: 400 micrograms
regadenoson interactions
The procedure team should review all medicines, drinks and supplements beforehand. Important interactions include:
Caffeine and other methylxanthines
They block adenosine receptors and can reduce the vasodilator effect, potentially impairing the diagnostic test.
Theophylline or aminophylline
These can oppose regadenoson's effect; aminophylline may also worsen or prolong a regadenoson-associated seizure.
Dipyridamole
It raises adenosine concentrations and may alter or intensify the response.
Sources
These sources were used to prepare and review this medicine page.
iatroX CPD
Keep a note for CPD
Save a private reflection with this source attached. Your first is free.
Record learning (opens in a new tab)Prepared and reviewed by the iatroX editorial team.